First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Lindsey R. Baden, Dan H. Barouch, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2012Cited by 168
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled TrialStephen R. Walsh, Lindsey R. Baden, Marissa B. Wilck et al.|The Journal of Infectious Diseases|2013Cited by 76
Safety and Immunogenicity of Modified Vaccinia Ankara (ACAM3000): Effect of Dose and Route of AdministrationMarissa B. Wilck, Raphael Dolin, Michael S. Seaman et al.|The Journal of Infectious Diseases|2010Cited by 74
Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of HumansLindsey R. Baden, Dan H. Barouch, Jinyan Liu et al.|The Journal of Infectious Diseases|2014Cited by 64
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R. Baden, Kelly Stanley, Marinela Kirilova et al.|The Journal of Infectious Diseases|2018Cited by 45